Conatus to Present at Upcoming Investor Conferences
March 27 2017 - 7:30AM
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the
company’s scheduled presentations at two upcoming investor
conferences in New York:
- H.C. Wainwright NASH Investor Conference at 2:20 p.m. ET on
Monday, April 3.
- 16th Annual Needham Healthcare Conference at 3:00 p.m. ET on
Tuesday, April 4.
Webcasts of both conference presentations will be available in
the Investors section of the company’s website at
www.conatuspharma.com.
About Conatus PharmaceuticalsConatus is a
biotechnology company focused on the development and
commercialization of novel medicines to treat liver disease.
Conatus is developing its lead compound, emricasan, for the
treatment of patients with chronic liver disease. Emricasan is
designed to reduce the activity of enzymes that mediate
inflammation and apoptosis. Conatus believes that by reducing the
activity of these enzymes, emricasan has the potential to interrupt
the disease progression across the spectrum of liver disease. For
additional information, please visit www.conatuspharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts contained in
this press release are forward-looking statements, including
statements regarding emricasan’s potential to interrupt the disease
progression across the spectrum of liver disease. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplates,” “believes,”
“estimates,” “predicts,” “potential” or “continue” or the negative
of these terms or other similar expressions. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of risks, uncertainties and
assumptions, including those risks described in the company’s prior
press releases and in the periodic reports it files with the
Securities and Exchange Commission. The events and
circumstances reflected in the company’s forward-looking statements
may not be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements.
Except as required by applicable law, the company does not plan to
publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
CONTACT: Alan Engbring
Conatus Pharmaceuticals Inc.
(858) 376-2637
aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Sep 2023 to Sep 2024